

APPLICATION NO.

09/558,871

MS-LC340

27581

# UNITED STATES PATENT AND TRADEMARK OFFICE

FILING DATE

04/28/2000

12/30/2003

7590

710 MEDTRONIC PARKWAY NE

MINNEAPOLIS, MN 55432-5604

MEDTRONIC, INC.





UNITED STATES DEPARTMENT OF COMMERCE United States Faient and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOLE 1400 Alguardia, Vinginia 22313-1450

ATTORNEY DOCKET NO. CONFIRMATION NO.

P-8873 3151

EXAMINER

DROESCH, KRISTEN L

ART UNIT PAPER NUMBER

3762

DATE MAILED: 12/30/2003

16

Please find below and/or attached an Office communication concerning this application or proceeding.

FIRST NAMED INVENTOR

John F. Norris

	_		_		5,~	
		Application	No.	Applicant(s)		
,		09/558,871		NORRIS ET AL.		
	Office Action Summary	Examiner		Art Unit		
		Kristen L Dr		3762		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1)⊠	Responsive to communication(s) filed on <u>02 D</u>	ecember 20	<u>03</u> .			
2a) <u></u> ☐	This action is <b>FINAL</b> . 2b)⊠ This	action is nor	n-final.			
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) 2-8,10,13-15,17-22,25,30-43 and 45-58 is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) 2-8,10,12-15,17-21,25,30 and 45-58 is/are allowed.						
6) Claim(s) 22, 31-34,37,43 is/are rejected.						
	7) Claim(s) 35,36 and 38-42 is/are objected to.					
8)∐	Claim(s) are subject to restriction and/o	or election re	quirement.			
Applicat	tion Papers					
9) The specification is objected to by the Examiner.						
10)⊠	10)⊠ The drawing(s) filed on <u>28 April 2000</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
	Replacement drawing sheet(s) including the correct					
11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. §§ 119 and 120						
12)						
Attachme				. (DTO 440) B====^!	(a)	
2) Not	ice of References Cited (PTO-892) ice of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449) Paper No(s)		4) Interview Summary 5) Notice of Informal I 6) Other:			

Page 2

Application/Control Number: 09/558,871

Art Unit: 3762

#### **DETAILED ACTION**

## Claim Objections

1. Claim 22 is objected to because of the following informalities: "(iii) differences in T-wave characteristics over a series of two or more heartbeats" merely restates what has already been set forth in the claim language. Appropriate correction is required.

## Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 3. Claims 22 and 31 are rejected under 35 U.S.C. 102(e) as being anticipated by Levine et al. (6,058,328).

With respect to claim 22, Levine et al. shows a device and method comprising sensing electrical cardiac activity using an implanted sensor and evaluating cardiac risk based on a comparison of the indication of T-wave alternans to a predetermined criterion based on analysis of differences in T-wave characteristics (time of occurrence following Q wave) over a series of two or more heartbeats (Col. 13, line 34-Col. 14, line 53, Col. 28, line 38-Col. 29, line 16, Col. 33, lines 42-61).

Regarding claim 31, Levine et al. shows an implantable medical device comprising a pacing generator, one or more leads coupled to the pacing generator, an electrical cardiac activity sensor, and a T-wave analyzer responsive to the sensor that controls the pacing generator to

Application/Control Number: 09/558,871

Art Unit: 3762

٦

generate increases rate electrical pacing stimuli, and analyzes cardiac risk based on a comparison of the indication of T-wave alternans to a predetermined criterion (Col. 15, line 14-30, Col. 13, line 34-Col. 14, line 53, Col. 28, line 38-Col. 29, line 16, Col. 33, lines 42-61).

The functional language and statements of intended use have been carefully considered but are not considered to impart any further structural limitations over the prior art.

With respect to claim 32, Levine et al. shows a memory (Col. 28, lines 55-59).

Regarding claim 33, Levine et al. shows providing an alert by initiating preemptive tachycardia pacing therapy.

Regarding claim 34, Levine et al. shows the T-wave analyzer analyzes differences in the OT interval over a series of two or more heartbeats to evaluate cardiac risk (Col. 33, lines 42-61).

With respect to claim 37, Levine et al. shows the T-wave analyzer analyzes differences in the T-wave characteristics (time of occurrence following Q wave) over a series of two or more heartbeats to evaluate cardiac risk (Col. 33, lines 42-61).

With respect to claim 43, Levine et al. shows a pacing generator that applies pacing stimuli and a processor or controller that controls the pacing generator based on the indication of T-wave alternans (Col. 13, line 34-Col. 14, line 53, Col. 15, line 14-30, Col. 28, line 38-Col. 29, line 16, Col. 33, lines 42-61).

The functional language and statements of intended use have been carefully considered but are not considered to impart any further structural limitations over the prior art.

Application/Control Number: 09/558,871 Page 4

Art Unit: 3762

١

## Allowable Subject Matter

4. Claims 2-8, 10, 12, 13-15, 17-21, 25, 30, and 45-58 are allowed.

5. Claims 35-36, and 38-42 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

## Response to Arguments

- 6. Applicant's arguments filed 10/7/03 have been fully considered but they are not persuasive.
- 7. Regarding claim 31, the addition of "whereby the desired physiological conditions for a T-wave alternans analysis can be invoked" is deemed to be language of intended use and therefore has not been considered to impose any structural limitations on the device as claimed. Levine et al. applies increased rate pacing as preemptive tachyarrhythmia therapy to shorten the QT interval (Col. 33, lines 51-57). But, it is possible that the desired physiological conditions for T-wave alternans analysis can be invoked by the increased pacing rate stimuli applied as preemptive tachyarrhythmia therapy since it would be dependent on the individual patient's physiological response.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kristen L Droesch whose telephone number is 703-605-1185. The examiner can normally be reached on M-F, 10:00 am - 6:00 pm.

Application/Control Number: 09/558,871

Kristen Droesch

Art Unit: 3762

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angie Sykes can be reached on 703-308-5181. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0858.

kld

ANGELA D. SYKES SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 3700

Cingel. D. Aller